Jpmorgan Chase & CO Nuvation Bio Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 76,484 shares of NUVB stock, worth $169,029. This represents 0.0% of its overall portfolio holdings.

Number of Shares

76,484

Previous 58,170 31.48%

Holding current value

$169,029

Previous $211,000 5.69%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$2.58 - $3.69 $47,250 - $67,578	18,314 Added 31.48%	76,484 $223,000
Q1 2024 May 10, 2024	SELL	$1.46 - $3.97 $59,414 - $161,559	-40,695 Reduced 41.16%	58,170 $211,000
Q4 2023 Feb 12, 2024	SELL	$0.96 - $1.53 $612 - $976	-638 Reduced 0.64%	98,865 $149,000
Q3 2023 Nov 14, 2023	SELL	$1.26 - $2.1 $17,750 - $29,584	-14,088 Reduced 12.4%	99,503 $133,000
Q2 2023 Aug 11, 2023	BUY	$1.56 - $1.84 $36,911 - $43,536	23,661 Added 26.31%	113,591 $204,000
Q1 2023 May 18, 2023	BUY	$1.6 - $2.48 $142,665 - $221,131	89,166 Added 11670.94%	89,930 $149,000
Q1 2023 May 11, 2023	SELL	$1.6 - $2.48 $105,452 - $163,451	-65,908 Reduced 98.85%	764 $1,000
Q4 2022 Feb 13, 2023	BUY	$1.68 - $2.5 $3,012 - $4,482	1,793 Added 2.76%	66,672 $128,000
Q3 2022 Nov 14, 2022	SELL	$0.29 - $4.04 $38,227 - $532,552	-131,820 Reduced 67.02%	64,879 $145,000
Q2 2022 Aug 11, 2022	SELL	$3.24 - $5.85 $1.68 Million - $3.03 Million	-518,701 Reduced 72.51%	196,699 $638,000
Q1 2022 May 11, 2022	BUY	$4.6 - $8.83 $198,623 - $381,270	43,179 Added 6.42%	715,400 $3.76 Million
Q4 2021 Feb 10, 2022	BUY	$7.75 - $10.05 $4.81 Million - $6.23 Million	620,362 Added 1196.25%	672,221 $5.71 Million
Q3 2021 Nov 12, 2021	BUY	$7.78 - $10.0 $403,463 - $518,590	51,859 New	51,859 $516,000

Others Institutions Holding NUVB

# of Institutions

152

Shares Held

123M

Call Options Held

9.7K

Put Options Held

6.5K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $480M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Nuvation Bio Inc. Transaction History